Sensipar (Cinacalcet HCl)

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Secondary Hyperparathyroidism

Conditions

Secondary Hyperparathyroidism

Trial Timeline

May 1, 2006 → May 1, 2011

NCT ID

NCT00261950

About Sensipar (Cinacalcet HCl)

Sensipar (Cinacalcet HCl) is a phase 2 stage product being developed by Amgen for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT00261950. Target conditions include Secondary Hyperparathyroidism.

What happened to similar drugs?

13 of 20 similar drugs in Secondary Hyperparathyroidism were approved

Approved (13) Terminated (0) Active (7)

✅Cinacalcet HClKyowa KirinApproved

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅RanibizumabNovartisApproved

✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved

✅RanibizumabNovartisApproved

✅Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00261950	Phase 2	Completed	May 1, 2006	May 1, 2011	Secondary Hyperparathyroidism

Competing Products

20 competing products in Secondary Hyperparathyroidism

See all competitors

Product	Company	Stage	Hype Score
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	38
KHK7580	Kyowa Kirin	Phase 1	29
KHK7580	Kyowa Kirin	Phase 3	40
KHK7580	Kyowa Kirin	Phase 3	40
Cinacalcet HCl	Kyowa Kirin	Approved	43
KHK7580 + Cinacalcet Hydrochloride	Kyowa Kirin	Phase 3	40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493	Kyowa Kirin	Phase 2	35
dirucotide + Placebo	Eli Lilly	Phase 2/3	38
dirucotide	Eli Lilly	Phase 2/3	30
Paricalcitol + Calcitriol	AbbVie	Pre-clinical	18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo	AbbVie	Phase 3	40
Paricalcitol + Calcifediol	AbbVie	Approved	43
Paricalcitol + Darbepoetin alfa	AbbVie	Approved	43
Birabresib Dose 20 mg	Merck	Phase 1	21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	47
Ranibizumab	Novartis	Approved	43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	43